No-tobacco day targets workplace as UN world health campaign moves into fifth year

Article Abstract:

Tobacco-free workplaces is the theme of the World Health Organization's (WHO) fifth World No-Tobacco Day on May 31, 1992. According to WHO, 60% of US companies now place some restrictions on tobacco use in the workplace, up from 16% in 1980. Thirty-eight percent of US companies banned smoking in the workplace altogether in 1991, up from 25% in 1990. WHO officials stress that companies must also counsel smokers and encourage them to quit. Another concern of nations participating in the 1992 World Health Assembly is the marketing of tobacco products in developing countries. In addition to lung cancer, tobacco may be responsible for many cases of cancer, emphysema, coronary heart disease and stroke. The American Cancer Society, the American Heart Association and the American Lung Association want to make the US tobacco-free by the year 2000.

Social policy, Political aspects, Antismoking movement, World Health Organization

---

Lipoprotein patterns, plaque, homocysteine, and hormones among ongoing cardiology studies

Article Abstract:

Cardiovascular researchers discussed their research at a 1996 conference. Advances in technology may allow many patients with heart disease to rehabilitate at home. Depression may occur commonly in patients with heart disease but many doctors do not recognize it. Elevated homocysteine levels appear to be a risk factor for cardiovascular disease. Estrogen appears to protect against heart disease as shown by the increase in coronary artery disease in postmenopausal women. Apolipoprotein E, smoking, and obesity are also risk factors for heart disease.

Health aspects, Risk factors, Obesity, Heart diseases, Cardiac patients, Homocysteine

---

Prostate Detection Possibility

Article Abstract:

Researchers continue to refine the diagnostic tests for prostate cancer. The most common screening test is the prostate-specific antigen (PSA) test. Doctors are researching a substance called human kallikrein 2 (hK2) enzyme. This measurement could be useful when combined with a PSA measurement. Specifically, research shows that an unbound to total PSA level of 10% or less and a ratio of rising hK2 to falling unbound PSA of 0.25 or more indicates a 2-to-1 likelihood that a biopsy would be positive for prostate cancer.

Diagnosis, Prostate cancer, Prostate-specific antigen, Prostate specific antigen, Kallikrein

Similar abstracts:

• Abstracts: Red-letter day for women's health research. Urinary stress incontinence - removing the stigma
• Abstracts: Reform report: proposals given, public concerns aired about health care overhaul. Views at odds on health care reform plans
• Abstracts: Foot care program for patients with leprosy also may prevent amputations in persons with diabetes. Last USPHS leprosy hospital phasing out: research relocating to university
• Abstracts: Medical tests for men. Be a lover forever. The overlooked disease
• Abstracts: The best defense. Advice on dissent. The tie that blinds

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.